Hypoxia augments MHC class I antigen presentation via facilitation of ERO1‐α‐mediated oxidative folding in murine tumor cells. Issue 12 (18th October 2016)

• Record Type: Journal Article
• Authors: Kajiwara, Toshimitsu; Tanaka, Tsutomu; Kukita, Kazuharu; Kutomi, Goro; Saito, Keita; Okuya, Koichi; Takaya, Akari; Kochin, Vitaly; Kanaseki, Takayuki; Tsukahara, Tomohide; Hirohashi, Yoshihiko; Torigoe, Toshihiko; Hirata, Koichi; Sato, Noriyuki; Tamura, Yasuaki
• Is Part Of: European journal of immunology. Volume 46:Issue 12(2016)
• Page Start: 2842
• Page End: 2851
• Publication Date: 2016-10-18
• Subjects: Cancer immunity -- Disulfide bond -- Hypoxia -- MHC class I molecule -- Oxidoreductase; Immunology -- Periodicals; 616.079
• DOI: 10.1002/eji.201646525
• Languages: English
• ISSNs: 0014-2980

Abstract

Abstract : Tumor cells within a hypoxic region increase MHC class I antigen presentation via enhanced oxidative protein folding by hypoxia‐inducible ERO1‐α in collaboration with protein disulfide isomerase (PDI). Therefore, tumor cells under the condition of hypoxia activate tumor‐specific CTLs more strongly than do tumor cells cultured under the condition of normoxia. Abstract : To establish an effective cancer immunotherapy, it is crucial that cancer cells present a cancer‐specific antigen in a hypoxic area, a hallmark of the tumor microenvironment. Here, we show the impact of hypoxia on MHC class I antigen presentation in vitro and in vivo in murine tumors. Activation of antigen‐specific CTLs by tumor cells that had been pre‐incubated under a condition of hypoxia was enhanced compared with that by tumor cells pre‐incubated under a condition of normoxia. Cell surface expression of MHC class I‐peptide complex on the tumor cells was increased under a condition of hypoxia, thereby leading to higher susceptibility to specific CTLs. We show that the hypoxia‐inducible ER‐resident oxidase ERO1‐α plays an important role in the hypoxia‐induced augmentation of MHC class I‐peptide complex expression. ERO1‐α facilitated oxidative folding of MHC class I heavy chains, thereby resulting in the augmentation of cell surface expression of MHC class I‐peptide complex under hypoxic conditions. These results suggest that since the expression of MHC class I‐peptide complex is augmented in a hypoxic tumor microenvironment, strategies for inhibiting the function of regulatory T cells and myeloid‐derived suppressor cells and/or immunotherapy with immune checkpoint inhibitors are promising for improving cancer immunotherapy.